"Type 2 Diabetes: New Treatment Strategies" has been divided into six parts. If you have a broadband (high-speed) internet connection you can watch the program online. Please begin by clicking on Part One.

Video clips may appear jagged for the first few minutes until the entire segment has loaded.

Faculty Disclosure Information

James R. Gavin III, M.D., Ph.D.
Consultant for: Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, LifeScan, MannKind, Novartis, Pfizer, sanofi-aventis

James R. LaSalle, D.O., F.A.A.F.P.
Consultant for: GlaxoSmithKline, Pfizer, Takeda Pharmaceutical Company Limited Stock Shareholder for: Pfizer
Honorarium: GlaxoSmithKline, Pfizer, Takeda Pharmaceutical Company Limited

Richard W. Nesto, M.D.
Honorarium: GlaxoSmithKline, Takeda Pharmaceutical Company Limited

Acknowledgement of Commercial Support
This program is funded through an educational grant from GlaxoSmithKline.

Part One (9 min.) Includes: CME information, faculty introductions, importance of patient compliance and lifestyle change, patient profile: Cheryl Jackson, presentation with varied complaints and symptoms. play clip

Part Two (8 min.) Includes: Patient profile: Brian Pierce, varied presentation, increasing incidence of diabetes, importance of earlier intervention and lifestyle changes, prevention of β-cell deterioration, glucose-insulin animation. play clip

Part Three (8 min.) Includes: Combo of insulin resistance and β-cell dysfunction, UKPDS study, Kaiser Permanente study, benefits of TZDs, need for combination therapy, treatment of metabolic syndrome, importance of goal in patients already undergoing treatment for diabetes. play clip

Part Four (10 min.) Includes: Insulin and oral therapy, TZD effect on β-cell dysfunction, patient profile: Starr Hunter, importance of combination therapy and A1C goals, side effects of TZDs. play clip

Part Five (10 min.) Includes: Switching vs. adding agents, need for multiple agents, RESULT trial, multiple study results, TZD mechanism of action animation, Diabetic Prevention Program (DPP), importance of engaging and empowering patients, diabetes patient group setting. play clip

Part Six (11 min.) Includes: Cultural sensitivity and other compliance issues, patient profile: Richard Faust, Jr., importance of targeting insulin resistance and controlling risk factors, final thoughts and take-away messages. play clip